<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 358 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page357.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=358">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 358 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 358</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=358"><img src="../thumb/358.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Cytostatics - 23                                                               2020-04 / 321
       Indications: Monother.in metastat.breast Ca where card.risk   (S4) INJ. 41/26/0246. 50 mg/1 ml.  fer instillat.if exists, brain oed.with mass eff. may necessit.re-op.&
                    st
       incr., advanc.ovar.Ca where 1  line platin-bas.chemother.fail., in   711364-001: 1x5 ml vial, R17,14  remov.of waf./remnants.
       combinat.with bortezomib in progress.multipl.myeloma in pts.al-  711366-001: 1x10 ml vial, R34,27
       ready receiv.at least one prior ther.& have undergone/unsuit.for   For further details refer to manufact.prod.lit.  HALAVEN, Equity [P/S] &
       bone marr.transplant, AIDS-relat.Kaposi’s sarcoma with low CD 4   FLUDARA, (Sanofi) Genzyme [P/S]  Eribulin
                                                                  Indications: Monother.in pts.with loc.advanc./ metastat.breast Ca
       counts (&lt;200 CD 4 lymphocyt./mm ) & extens.mucocutan./ viscer.dis.
                     3
       (S4) LIPOSOMAL INFUS, A40/26/0389. 2 mg/ml  Fludarabine phosphate  who have progress.aft.at least 2 chemother.regimens for advanc.dis.
                                                                  Prior ther.to have incl.an anthracycline & a taxane unless pts.not suit.
                                     Indications: Init.treatm.of B-cell chron. lymphocyt. leukaem.(CLL)
       720412-001: 1x10 ml vial, R5 711,75
       For further details refer to manufac.prod.lit.  &.(CLL) pts.with suffic. bone marr. reserv.who have not respond to   (S4) SOL.FOR INJ, 48/26/0047. 0,88 mg/2 ml
                                     /whose dis. progress.dur.or aft.treatm.with at least one standard   718840-001: 1x2 ml, R5 406,48
       DOXORUBICIN ACCORD, Accord [P/S]  alkylat.agent contain. regimen.  For further details refer to manufact.prod.lit
       Doxorubicin HCl.              (S4) INJ, 28/26/0605         See also MDR page 306.
       Indications: Ac.lymphoblast./ac.myelogen. leukaem., lymphoma/   820997-005: 50 mg, 5 vials, R11 090,14  HYCAMTIN, Sandoz [P/S]
       some solid tumours, metastat. breast adenocarcin., bladd.& broncho-  (S4) TABS, 36/26/0422  Topotecan HCl equiv.to topotecan
       gen. Ca, neuroblastoma, metastat.thyroid Ca, Ca of endometrium/  710159-001: 10 mg, 20, R8 412,68  Indications: Palliat.treatm.of small cell lung Ca as a 2  line
                                                                                            nd
       testes/prostate/cervix/ head & neck, plasma-cell myeloma, ovar.Ca   For further details refer to manufac.prod.lit.  chemotherapeut.agent in pts.who relapse aft.an init.respon.to 1   st
       if admin. with cisplatin & cyclophosphamide, concom. with other cy-  FLURACEDYL, (Cipla Medpro) Teva [P/S]  line agents. INJ also: Metastat. ovary Ca aft.fail of 1st line/sub-
       totox.for breast Ca & small (oat)-cell lung Ca, range of sarcoma incl   5-Fluorouracil.  seq.ther., in combinat.with cisplatin for histologic. confirm. stage
       osteogen./ Ewing’s/soft-tiss., Hodgkin’s dis.in the ABVD combinat.,   Indications: Palliative managem.of Ca of breast & GI tract.  IV-B recurr./persist.cervix Ca not amenable to curat.treatm. with
       non-Hodgkin’s lymphoma in the BACOP combinat.  (S4) INJ. 35/26/0144, 0349, 0350, 0351. 50 mg/ml.  surg.&/radiat.ther.
       (S4) CONC.SOL.FOR INFUS, 46/26/0484, 0485. 2 mg/ml  711679-001: 250 mg, R16,30  (S4) INJ, 31/26/0300. 4 mg
       721804-001: 10 mg, 1x5 ml, R80,73  711136-001: 500 mg, R34,90  847909-018: 5x5 vials, R19 888,61
       721805-001: 50 mg, 1x25 ml, R403,65  706683-001: 1 000 mg, R79,50  (S4) CAPS, 42/26/0739, 0740
       For further details refer to manufac.prod.lit.  706684-001: 5 000 mg, R371,90  719444-001: 0,25 mg, 10, R2 598,67
       DOXORUBICIN-SOL PCH, (Cipla Medpro) Teva [P/S]  For further details refer to manufac.prod.lit.  719443-001: 1 mg, 10, R10 394,79
                                                                  For further details refer to manuf.product lit.
       Doxorubicin HCl.              GEMTAZ, Ranbaxy [P/S]
       Indications: In combinat.regimen for disseminat. neoplast.condits.  Gemcitabine HCl.  HYDREA, Equity [P/S]
       (S4) SOL.FOR INJ. Z/26/167, 169, 170. 2 mg/ml.  Indications: Loc.advanc./metastat.non-small cell lung Ca, 1st   Hydroxyurea.
       823635-008: 1x5 ml vial, R81,57  line treatm.in loc.advanc.non-resect. stage II & III or metast.stage   Indications: Anti-neoplast.agent for malign.dis.
       823643-019: 1x25 ml vial, R388,95  IV adenocarcinoma of pancreas, pts.prev.treat.with 5-FU, transit.  (S4) CAPS. H2753.
       837008-018: 1x100 ml multidos.vial, R1 946,93  cell bladd. Ca, unresect./loc.recurr./metastat.breast Ca in combin.  731706-005: 500 mg, 100, R273,50
       For further details refer to manufact.prod.lit.  with paclitaxel in pts.who have relaps. follow.adjuv./neo-adjuv.ther.  For further details refer to manufact.prod.lit.
       ELOPLAT, Sandoz [P/S]         where prior chemother. should have incl.an anthracycl.unless C/I.  IMATINIB ACCORD, Accord [P/S]
       Oxaliplatin                   (S4) POWD.FOR INJ. 41/26/0934, 0933  Imatinib
                                     715251-001: 200 mg, 5 vials, R330,15
       Indications: In combinat.with 5-fluorouracil & folinic acid for met-  Indications: Adults & paed.pts: New.diagn Philadelph. chromo-
       astat.colorect.Ca and adjuv. treatm.of stage III (Dukes’ C) colon Ca   715252-001: 1 g, 25 vials, R1 650,81  some posit.chron.myeloid leukaem (CML)., CML in blast crisis/ac-
       aft.compl. remov.of prim.tumour.   For further details refer to manufact.prod.lit.  celerat./ chron. phase aft.interferon-alpha ther.fail.
       (S4) CONC.FOR SOL.FOR.INFUS. 46/26/0919, 46/26/0920.  GEMZAR, Eli Lilly [P/S]  Adults: New.diagn Philadelph.chromosome posit. chron.myeloid
       3000404-001: 50 mg, 5 mg/ml, 1x10 ml, R930,39  Gemcitabine HCl.  leukaem (CML) integrat.with chemother., monother.in relaps./refract.
       3000405-001: 100 mg, 5 mg/ml, 1x20 ml, R1 860,84  Indications: Loc.advanc./metastat.non-small cell lung Ca, 1st line   Ph+ ALL, myelodysplast./ myeloproliferat.dis.assoc.with platel.-deriv.
       For further details refer to manufact.prod.lit.  treatm.in loc.advanc.non-resect. stage II & III or metast.stage IV ade-  growth fact.recept.gene re-arrangem., system. mastocytos.with-
                                                                  out D816V c-kit mutat.& eosinophil., hypereosinophilic syndr.&/or
       EPICORD, (Eurolab) Accord [P/S]  nocarcinoma of pancreas, pts.prev.treat.with 5-FU, transit.cell bladd.   chron. eosinophil.leukaem.wih FIP1L1-PDGFR alpha re-arrangem.,
                                     Ca, unresect./loc.recurr./metastat.breast Ca in combin.with paclitax-
       Epirubicin HCl                el in pts.who have relaps.follow.adjuv./neo-adjuv.ther.where prior   unresect.&/or metastat.malign. gastrointest. stromal tumours
       Indications: Mono chemother.for breast & gastr. Ca, malign.lym-  chemother.should have incl.an anthracycl.unless C/I, alone/in com-  (GIST), unresect, recurr. &/or metastat. dermafibrosarcoma protuber.
       phoma, soft-tiss.sarcoma., advanc. colorect.Ca, malign.melanoma.,   binat.for recurr.epithel.ovar.Ca relaps.follow.platin.bas.chemother.  (S4) TABS, 49/26/0740, 0741
       combinat.ther. with other chemotherapeut.agents for lung & ovar. Ca.  (S4) POWD.FOR INJ. 29/26/0306, 0307.  722780-001: 100 mg, 60, R6 051,76
       (S4) SOL.FOR INJ. 2 mg/ml, 42/26/0152, 0897  815799-004: 200 mg, sngl.vials, R361,20  722788-001: 400 mg, 30, R11 004,50
       716240-001: 10 mg, 1 vial, R131,28  815802-005: 1 g, sngl.vials, R1 806,05  For further details refer to manufact.prod.lit.
       716241-001: 50 mg, 1 vial, R656,41  For furth.details refer to prof.info.
       For further details refer to manufact.prod.lit.            IMAVEC, Cipla Medpro [P/S]
                                                                  Imatinib
       EPOSIN, (Cipla Medpro) Teva (P/S)  GLEEVEC, Novartis [P/S]  Indications: New.diagn Philadelph.chromosome positive chron.
                                     Imatinib
       Etoposide.                    Indications: Adult & paed.pts: New.diagn Philadelph.chromo-  myeloid leukaem (CML)., CML in blast crisis/accelerat./chron.phase
       Indications: Testicul.tumours, refract.testicul. tumours in pts.who   some positive chron.myeloid leukaem (CML)., CML in blast crisis/  aft.interferon-alpha ther.fail., adult pts.with unresect.&/or metastat.
       have receiv.surg.,chemo/ radiotherapy, small cell anaplast.lung tu-  accelerat./ chron. phase aft.interferon-alpha ther.fail.  malign.gastrointest.stromal tumours (GIST)
       mours & non-Hodgkin’s lymphoma esp.of large cell diffuse variety   Adult pts: New.diagn.Philadelph.chromosome positive   (S4) CAPS, 42/34/0496, 50/34/0118
       in combinat.with other chemotherapy.  ac.lymphoblast.leukaem. (Ph+ALL) intergrat. with chemother., re-  718595-001: 100 mg, 60, R6 578,00
       (S4) CONC.FOR INFUS. 32/26/0263. 20 mg/ml.  laps./refract.Ph+ ALL as monther., myelodysplast./myeloproliferat.  723296-001: 400 mg, 30, R12 648,85
       850926-010: 100 mg/5 ml, 1x5 ml vial, R196,40  dis. (MDS/MPD) assoc.with platelet-deriv.growth fact. recept.(PDG-  For furth.details refer to manufact.prod.lit.
       For further details, refer to manufact.prod.lit.  FR) gene re-arrangem., system. mastocytos. (SM) without the D816V   IMBRUVICA, Janssen Pharmaceutica [P/S]
       ERBITUX, Merck (Biopharma Division)  c-Kit mutat.& eosinophil., hypereosinophil.syndr.(HES) &/chron. eo-  Ibrutinib
       See Section 26                sinophil.leukaem.(CEL) with FIP1L1-PDGFR alpha rearrangem., un-  Indications: Mantle cell lymphoma (MCL) in adults who have re-
                                                                  ceived at least one prior ther., relapsed chron.lymphocyt.leukaem.
                                     resect.&/or metastat.malign. gastrointest. stromal tumours (GIST),
       ERIOX, Eurolab [P/S]          adjuv.treatm. follow.resect.of Kit-posit.GIST, unresect./recurr.&/   (CLL) in adults, prev.untreat.CLL in adults, Waldenstroms mac-
       Docetaxel anhydr.             metastat.dermatofibrosarcoma protuberans (DFSP)  roglobulinaem. (WM)
       Indications: Loc.advanc./metastat.breast Ca in combinat.with dox-  (S4) TABS, 38/34/0143, 0144  (S4) CAPS, 50/26/0939
       orubicin in pts.who have not receiv. cytotox. ther.for this condit., loc.  705491-001: 100 mg, 60, R23 290,92  721691-001: 140 mg, 90, R103 933,84
       advanc./ metastat.breast Ca aft.fail.of cytotox.ther., in combin. with   705490-001: 400 mg, 30, R46 581,87  721691-002: 140 mg, 120, R138 578,45
       capecitabine for loc.advanc.or metastat. breast Ca aft.fail.of cytotox.  For further details refer to manufacturers prod. lit.  For further details refer to manufact.prod.lit
       chemother. Prev. ther.should have incl.an anthracycline, in combinat.   INTAS OXALIPLATIN, Eurolab [P/S]
       with cisplatin for unresect.loc.advanc./ metastat. non-small cell lung   GLIADEL, Litha [P/S]  Oxaliplatin
                                     Carmustine.
       Ca when chemother. not prev. admin.for this condit., loc.advanc./   Indications: Surg.adjunct.to prolong surviv.in recurr.glioblastoma   Indications: In combinat.with 5-fluorouracil & folinic acid for meta-
       metast. non-small cell lung Ca even aft.fail.of platinum-bas. chem-  multiforme where surgic. resect.indicat., adjunct to surg.& radiat.  stat. colorect.Ca and adjuv. treatm.of colon Ca.
       other., metastat.ovarian Ca.aft. fail.of 1st line /subseq.chemother., in   in new. diagn.high-grade malign.glioma pts.  (S4) LYOPHILIZ.POWD.FOR SOL.FOR INFUS., 44/26/0380,
       combin.with prednisone/prednisolone for androg. independ. (horm.  (S4) WAFER. 32/26/0111  42/26/1066
       refract.) metastat.prostate Ca.  702507-003: 7,7 mg/wafer, 8, R138 393,44  717829-001: 50 mg, sngl.vials, R930,41
       (S4) CONC.FOR INFUS, 42/26/0006, 42/34/0007. 42/26/0008,   Dosage: Aft.tumour resect., pathology confirm.& haemostasis obt.   717830-001: 100 mg, sngl.vials, R1 860,82
       42/34/0009                    Place upto 8 wafers in resect. cav.otherwise place the max.space   For further details refer to manufact.product lit.
       719959-001: 20 mg, 1x 6 ml vial + dil, R789,77  & shape allow. Slight overlap.permiss.but do not break wafers in
       719960-001: 80 mg, 1x 15 ml vial + dil, R3 159,05  more than half. Do not exceed 8 wafers. To secure against cavity   IRINOTAS, Eurolab [P/S]
       For further details refer to manufact.prod.lit.  surf.place oxidis.regener.cellulose over wafers. Irrig.resect.cavity   Irinotecan HCl trihydrate.
       ERIVEDGE, Roche [P/S]         and close dura in water tight fashion.  Indications: Advanc.colorect.Ca with WHO perform. status of 2
                                                                  or low.in combinat.with 5-fluorouracil and folinic acid without prior
       Vismodegib                    Contra indications: Safety in pregn., lactat.& childr. not est.  chemother. for advanc.dis. or as sngl.agent when est. 5-fluoroura-
       Indications: Adult pts.with symptomat.metastat. bas.cell Ca, loc.  Side effects: Cerebr.haemorrh./infarct., periph./ brain oed., neck/  cil contain.regim.has fail.
       advanc.bas.cell Ca inappropriate for surg/radiother.  back & chest pain, accid.injury, allerg.reacts., asthen., sepsis, GI   (S4) SOL.FOR INFUS. 41/26/1003, 44/26/0024. 20 mg/ml
       (S4) CAPS, 48/32.16/0658      disturbs., hyponatraem., hyperglycaem., hypokalaem., CNS effs.  712643-001:, 40 mg/2 ml, sngl.dos.vial, R420,73
       722592-001: 150 mg, 28, R73 208,39.  incl.hydrocephal/monopleg./coma, urin. incontin., hyper-/hypo-  712873-001: 100 mg/5 ml, sngl.dos.vial, R1 051,83
       For further details refer to prof. info.  tens., bld dyscras., infects., vis.disturbs., abnorm.heal., aphas.,   For further info.refer to manuf.product lit.
                                     convuls., hemipleg., IC hypertens., meningit., abscess, deep throm-
       FLORACOR, Accord [P/S]        bophlebit., pulm.embol.      KEY-DOCETAXEL, Key Oncologics [P/S]
       5-Fluorouracil.               Special precautions: Wear double surg.gloves when handl.,   Docetaxel trihydr.equiv.to docetaxel anhydr.
       Indications: Palliat.of breast & GI tract Ca. Benefic.in hepatoma &   monit.pts.for known poss.complicat. of craniotomy, avoid commu-  Indications: In combinat.with doxorubicin & cyclophosphamide,
       Ca ovary, cervix, bladder, prostate, pancreas, oropharyngeal areas.  nicat.betw.surg. resect. cavity & ventricul.syst.& close prior to wa-  indic.for adjuv.ther.for oper. node-pos.breast Ca, combin.with</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page357.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>
             </td>
             <td width="35%"><a href="page359.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page359.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
